Genetic Screening for Ehlers-Danlos Syndrome (EDS): A Comprehensive Guide
By Brandon Colby, MD, Genomics Specialist
Last Updated: February 27, 2025
What is Ehlers-Danlos Syndrome?
Ehlers-Danlos syndrome (EDS) refers to a group of inherited connective tissue disorders that affect collagen, a protein providing strength and elasticity to tissues including skin, joints, blood vessels, and organs. Faulty collagen caused by genetic variants leads to various EDS symptoms.
- Joint hypermobility (flexible joints)
- Stretchy skin that bruises easily
- Tissue fragility
- Chronic pain
- Joint instability and recurrent dislocations
- Cardiovascular issues (in some types)
Types of Ehlers-Danlos Syndrome
- Prevalence: 1 in 3,100 - 5,000
- Genes: Unknown (Preliminary research has identified a potential link between the KLK15 gene and hEDS.)
- Protein: Unknown
- Inheritance: Autosomal Dominant
- Features: Joint hypermobility, instability, chronic pain
- Prevalence: 1 in 20,000 - 40,000
- Genes: COL5A1, COL5A2, COL1A1
- Protein: Type V collagen, Type I collagen
- Inheritance: Autosomal Dominant
- Features: Skin fragility with scars, stretchy velvety skin
- Prevalence: 1 in 100,000 - 200,000
- Genes: COL3A1, COL1A1
- Protein: Type III collagen, Type I collagen
- Inheritance: Autosomal Dominant
- Features: Arterial and organ fragility, extensive bruising, pneumothorax
- Prevalence: <1 in 1,000,000
- Genes: C1R, C1S
- Protein: C1r, C1s
- Inheritance: Autosomal Dominant
- Features: Early gum disease, tooth loss, pretibial plaques
Genetics and Inheritance of EDS
- Autosomal Dominant: One pathogenic gene variant causes the condition (50% chance of passing to children; affects both genders equally). Types: hEDS, cEDS, vEDS, pEDS.
- Autosomal Recessive: Two pathogenic variants required (both parents must be carriers; each child has a 25% chance). Types: Kyphoscoliotic, Spondylodysplastic, Classical-like.
Genetic Screening for EDS
- Symptoms suggesting EDS
- Family history
- Severe symptoms or complications (arterial rupture, organ fragility)
- Definitive diagnosis needed for management
- Family planning
- Single Gene Analysis: Specific suspected types (e.g., COL3A1 for vEDS)
- Multi-Gene Panel: Multiple genes tested simultaneously for unclear types
- Whole Exome Sequencing (WES): Comprehensive, used in complex or unresolved cases
Genetic Screening by EDS Type
Currently, there is no confirmed genetic cause for hEDS, and diagnosis is based on clinical evaluation of symptoms.
Preliminary research has identified a potential link between the KLK15 gene and hEDS.
Our comprehensive genetic screening includes all genes associated with EDS, including the KLK15 variant.
However, the genetic basis of hEDS remains unclear, and ongoing research is needed to establish any definitive connection.
- Positive Result: Confirms diagnosis, guides management, family testing
- Negative Result: Condition unclear or undetected, especially hEDS
- Variant of Uncertain Significance (VUS): Unknown clinical impact; managed by symptoms, not genetics alone
- Definitive diagnosis for most types
- Informed medical management and monitoring
- Family planning decisions
- Advances research into treatment
- No test for hEDS, Preliminary research has identified a potential link between the KLK15 gene and hEDS.
- Genetic complexity (multiple genes)
- Testing limitations (variant detection)
- Variants of uncertain significance
- Cost and insurance coverage challenges
- Genetic screening advised if symptoms, family history, or severe complications exist.
- Consumer tests (23andMe, Ancestry) do not diagnose EDS.
- Negative genetic tests don’t rule out EDS (especially hEDS).
- Rarely, multiple EDS types may coexist.
- Insurance coverage varies; prior authorization may help.
Additional Resources
- Sequencing.com’s EDS Screening Test
- The Ehlers-Danlos Society
- HEDGE Study
- Ehlers-Danlos National Foundation
- NIH Rare Diseases Information
About The Author
Dr. Brandon Colby MD is a US physician specializing in the personalized prevention of disease through the use of genomic technologies. He’s an expert in genetic testing, genetic analysis, and precision medicine. Dr. Colby is also the Founder of Sequencing.com and the author of Outsmart Your Genes.
Dr. Colby holds an MD from the Mount Sinai School of Medicine, an MBA from Stanford University’s Graduate School of Business, and a degree in Genetics with Honors from the University of Michigan. He is an Affiliate Specialist of the American College of Medical Genetics and Genomics (ACMG), an Associate of the American College of Preventive Medicine (ACPM), and a member of the National Society of Genetic Counselors (NSGC).